Skip to content
drillr.ai

INSM

Insmed Incorporated

NASDAQ · USHealthcareBiotechnology
$107.02-1.20%

Price as of Jul 20, 2026

INSM news

Insmed Incorporated news

A server-rendered, paginated timeline of the latest available company news.

  1. Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire BRIDGEWATER, N.J., June 4, 2026 BRIDGEWATER, N.J., June 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 103 new employees. The awards were granted under the Insmed Incorporated 2025 Induc

    PR Newswire ·

  2. Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

    Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update PR Newswire BRIDGEWATER, N.J., May 7, 2026 — Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI(®) (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025— — ARIKAYCE(®) (amikacin liposome inhalation suspension) Revenues of $98.1 Million for the First Quarter of 2026, Reflecting 6% Growth Over the First Quarter

    PR Newswire ·

  3. Insmed Provides Clinical Update on Phase 2b CEDAR Study

    Insmed Provides Clinical Update on Phase 2b CEDAR Study PR Newswire BRIDGEWATER, N.J., April 7, 2026 —Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program— —Safety Was Consistent with Previous Studies and No New Safety Signals Were Identified for Either Dose of Brensocatib— BRIDGEWATER, N.J., April 7, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class thera

    PR Newswire ·